ersodetug
mAbexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
2
Phase 4
0
Earliest trial started Jan 11, 2024 (NCT06208215)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 3 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Insulin receptorINHIBITOR
INSR inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314739 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06881992 | Phase 3 | Apr 16, 2025 | Rezolute |
| NCT06208215 | Phase 3 | Jan 11, 2024 | Rezolute |
| NCT07262970 | N/A | — | Rezolute |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Rezolute | For profit | 3 | 3 | 2 | 2024 |
1 organizations
Page 1 / 1